Skip to main content
. 2014 Jun 30;18(7):1372–1380. doi: 10.1111/jcmm.12284

Table 2.

Effect of TLR4 blocking on cytokine secretion by HPV vaccine-stimulated IL-15 DC

No stimulus (pg/ml) LPS HPV vaccine


No CLI095 (pg/ml) With CLI095 (pg/ml) No CLI095 (pg/ml) With CLI095 (pg/ml)
Typical Th1-polarizing
IFN-γ 17 ± 6 2735 ± 1121 38 ± 15** 781 ± 368 41 ± 15*
IL-12p70 0 ± 0 28 ± 8 0 ± 0 0 ± 0 0 ± 0
IL-2 1 ± 1 4 ± 1 1 ± 1 2 ± 1 1 ± 0
Typical Th2-polarizing
IL-4 1 ± 0 3 ± 1 1 ± 0 1 ± 0 0 ± 0
IL-5 0 ± 0 5 ± 1 1 ± 0 2 ± 1 1 ± 0
IL-10 2 ± 1 659 ± 614 33 ± 29 125 ± 115 1 ± 0
IL-13 2 ± 2 16 ± 4 2 ± 2 7 ± 2 0 ± 0
Pro-inflammatory
IL-1β 61 ± 46 1452 ± 84 170 ± 38** 697 ± 322 109 ± 15*
TNF-α 37 ± 12 8443 ± 226 345 ± 273*** 3430 ± 1699 447 ± 273*

CLI095, TLR4 inhibitor; HPV, human papillomavirus; IFN, interferon; IL, interleukin; Th, T helper; TLR4, Toll-like receptor 4; TNF, tumor-necrosis factor; LPS, lipopolysaccharide.

*P < 0.05, **P < 0.01, ***P < 0.001 (compared between CLI095 and no CLI095 added; n = 2).